Does Blue Cross Blue Shield Cover Symbicort?

Yes. Generic budesonide/formoterol is covered as the preferred option on most BCBS commercial and Medicare Part D plans, typically at a lower Tier 2 cost. This is the covered path BCBS intends — brand Symbicort is non-preferred or excluded on many plans. BCBS is 30-plus licensees, so the exact tier varies; verify on your specific Blue plan's drug list.

Brand Symbicort is frequently non-preferred on BCBS commercial plans and, on some BCBS Medicare Part D formularies, is not covered at all. Since generic budesonide/formoterol is therapeutically equivalent and preferred, BCBS has little incentive to place brand Symbicort at a favorable tier. Verify whether brand Symbicort is even listed on your specific BCBS licensee's formulary.

BCBS Medicare Part D plans typically cover generic budesonide/formoterol. Brand Symbicort is often not covered on Part D — it may not appear on the formulary at all, or may be on a non-preferred tier with very high cost-share. The $2,100 Part D out-of-pocket cap in 2026 limits total exposure if you end up on a higher-cost path. Verify on your BCBS Medicare plan's drug list.

Step therapy requires trying a less expensive inhaler first before an insurer will approve a combination ICS/LABA inhaler. Some BCBS plans require a documented trial of an ICS alone (such as generic fluticasone) before approving generic budesonide/formoterol. If your asthma or COPD requires combination therapy, your prescriber can document clinical necessity to satisfy or bypass the step requirement.

Symbicort has a generic (budesonide/formoterol) that is preferred and lower-cost; brand Symbicort is often non-preferred or excluded. Trelegy Ellipta is brand-only — no generic exists — so coverage is not about generic-vs-brand but about whether your BCBS plan attaches prior authorization or step therapy to the brand. The coverage logic is the inverse of each other within the same BCBS formulary.